Medivir's research partner, Peptimmune, attracts USD 41.2m
MEDIVIR'S RESEARCH PARTNER, PEPTIMMUNE, ATTRACTS USD 41.2m FROM INVESTORS JOINT CATHEPSIN S INHIBITOR PROJECT CONTINUED AGGRESIVELY The American biotech corporation, Peptimmune, has recently obtained USD 41.2 million from American investors. As a consequence, Medivir's cathepsin s inhibitor project, partnered with Peptimmune, will benefit and will continue to be pursued aggressively towards the clinical phases of pharmaceutical development. Cathepsin S is a protease with a fundamental function in immunological processes and autoimmune diseases. Medivir has developed potent compounds which